LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

Search

MannKind Corp

Slēgts

SektorsVeselības aprūpe

4.15 0.97

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.15

Max

4.18

Galvenie mērījumi

By Trading Economics

Ienākumi

5.7M

13M

Pārdošana

1.6M

78M

P/E

Sektora vidējais

41.2

53.54

EPS

0.04

Peļņas marža

16.793

Darbinieki

403

EBITDA

8.3M

27M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+140.96% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 6. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-255M

1.3B

Iepriekšējā atvēršanas cena

3.18

Iepriekšējā slēgšanas cena

4.15

Ziņu noskaņojums

By Acuity

34%

66%

91 / 381 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

MannKind Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 31. maijs 10:30 UTC

Top Ziņas

Pension Funds Won't Save the Bond Market -- Heard on the Street -- WSJ

2025. g. 31. maijs 06:30 UTC

Peļņas

5 Things We've Learned From Retail Earnings -- Barrons.com

2025. g. 31. maijs 04:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 30. maijs 23:51 UTC

Iegādes, apvienošanās, pārņemšana

Trump Raises Steel Tariffs, Saying U.S. Steel Will Remain U.S.-Controlled -- Update

2025. g. 30. maijs 21:30 UTC

Top Ziņas

Stocks Shrug Off Trade War to Post Best Month Since 2023 -- WSJ

2025. g. 30. maijs 21:15 UTC

Top Ziņas

The Score: E.l.f. Beauty, Tesla, Nvidia, and More Stocks That Defined the Week -- WSJ

2025. g. 30. maijs 20:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2025. g. 30. maijs 20:44 UTC

Iegādes, apvienošanās, pārņemšana

Bill Ackman Is Killing It. A New ETF Will Track His Investments. -- Barrons.com

2025. g. 30. maijs 20:24 UTC

Top Ziņas

Major U.S. Stock Indexes Finish About Flat; U.S.-China Trade Friction Renews -- WSJ

2025. g. 30. maijs 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 30. maijs 19:44 UTC

Tirgus saruna

Gold Breaks 4-Month Winning Streak -- Market Talk

2025. g. 30. maijs 19:38 UTC

Tirgus saruna

Companies Delay or Cancel $14B In Clean-Energy Investments -- Market Talk

2025. g. 30. maijs 19:29 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

NRG Energy and UnitedHealth Are the S&P 500's Best and Worst for May. Here's Why. -- Barrons.com

2025. g. 30. maijs 19:14 UTC

Tirgus saruna

Oil Settles Lower Ahead of OPEC+ Output Decision -- Market Talk

2025. g. 30. maijs 19:05 UTC

Tirgus saruna

U.S. Natural Gas Futures Fall Awaiting Hotter Weather -- Market Talk

2025. g. 30. maijs 18:51 UTC

Tirgus saruna

Canada's Retaliatory Tariffs Help Fuel Sizable Rise in Tax Revenue -- Market Talk

2025. g. 30. maijs 18:37 UTC

Tirgus saruna
Peļņas

Costco Well Positioned for Sustainable Growth, UBS Says -- Market Talk

2025. g. 30. maijs 18:04 UTC

Top Ziņas

S&P 500 Falls After More Trump-China Friction -- WSJ

2025. g. 30. maijs 17:47 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 30. maijs 17:47 UTC

Tirgus saruna

Time for BoC Gov. Macklem to Cut Rates, Desjardins Says -- Market Talk

2025. g. 30. maijs 17:40 UTC

Iegādes, apvienošanās, pārņemšana

Trump Is Praising His U.S. Steel Deal. No One Is Sure What It Means -- WSJ

2025. g. 30. maijs 17:38 UTC

Tirgus saruna

U.S: Oil Rig Count Falls for Fifth Straight Week -- Market Talk

2025. g. 30. maijs 17:31 UTC

Tirgus saruna

Costco Well Positioned to Gain Share Amid Tariffs, Baird Says -- Market Talk

2025. g. 30. maijs 17:14 UTC

Top Ziņas

American Consumers Are Still Gloomy on the Economy -- 3rd Update

2025. g. 30. maijs 16:31 UTC

Peļņas

Ulta Beauty Stock Is Rising. Earnings Strength Was More Than Cosmetic. -- Barrons.com

2025. g. 30. maijs 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 30. maijs 16:20 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2025. g. 30. maijs 16:16 UTC

Top Ziņas

S&P 500 Falls After Trump Hits Out at China -- WSJ

2025. g. 30. maijs 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 30. maijs 16:14 UTC

Top Ziņas

HSBC Retreats From Banking Smaller U.S. Businesses -- WSJ

Salīdzinājums

Cenas izmaiņa

MannKind Corp Prognoze

Cenas mērķis

By TipRanks

140.96% augšup

Prognoze 12 mēnešiem

Vidējais 10 USD  140.96%

Augstākais 12 USD

Zemākais 9 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi MannKind Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

6

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

4.079 / 4.323Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Noskaņojums

By Acuity

91 / 381 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.